The purpose of this legislation is to extend and improve the Accelerating Access to Critical Therapies for ALS Act, which focuses on enhancing research and access to treatments for amyotrophic lateral sclerosis (ALS), a serious neurodegenerative disease. The act is reauthorized to continue its provisions through the fiscal year 2031, ensuring ongoing support for ALS research and treatment development. Key provisions of the legislation include extending the timeline for grants aimed at ALS research until 2031.